This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ATG-Fresenius S

INSYS Therapeutics, Inc.

Drug Names(s): anti-human-T-lymphocyte immune globulin, EZ-2053, US-ATG-F

Description: ATG-Fresenius S is a polyclonal antibody preparation. As opposed to monoclonal antibodies, it targets a range of antigens on activated T-cells and depletes T-cells that otherwise would result in an immunologic attack on the transplanted organ leading to its rejection.

Deal Structure: In January 2006, Enzon Pharmaceuticals announced it was returning its rights to ATG-Fresenius S to Fresenius Biotech GmbH, a subsidiary of the health care company Fresenius AG.

In October 2007, Fresenius Biotech and Nabi Biopharmaceuticals agreed to terminate the agreement for the clinical development and marketing of ATG-Fresenius S in North America. Fresenius Biotech will assume responsibility for the clinical development and registration of ATG-Fresenius S in the US.

In June 2013, Fresenius sold Fresenius Biotech to the Fuhrer family, owners of Neopharm. The transaction includes both products Removab and ATG-Fresenius S. The parties agreed not to disclose financial details of the transaction.


ATG-Fresenius S News

Pink Sheet Licensing In Brief


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug